Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of melanoma
3.2.1.2 Advancements in treatment options
3.2.1.3 Strategic collaborations and partnerships between market players
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of drug development
3.2.2.2 Stringent regulatory process for drug approval
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Targeted therapy drugs
5.3 Immunotherapy drugs
5.4 Chemotherapy drugs
5.5 Combination therapy
Chapter 6 Market Estimates and Forecast, By Melanoma Stage, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Early-stage melanoma
6.3 Advanced-stage melanoma
6.4 Metastatic melanoma
Chapter 7 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Branded
7.3 Generic
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Parenteral
8.4 Topical
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Amgen Inc.
10.3 AstraZeneca
10.4 Bayer AG
10.5 Bristol-Myers Squibb Company
10.6 F. Hoffman-La Roche Ltd.
10.7 Genentech, Inc
10.8 Merck & Co. Inc.
10.9 Mylan N.V.
10.10 Novartis AG
